Canaccord Genuity Maintains Buy on Definium Therapeutics, Lowers Price Target to $58
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ: DFTX ) with a Buy and lowers the price target from $60 to $58.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.